Eplerenone

Routes
Oral (PO)
Half-Life (t½)
PO: 3h
Formula
C24H30O6
Molecular Weight
414.49 g/mol
PubChem CID
443872
Aliases
Inspra

Pharmacological Mechanism

Selective mineralocorticoid receptor antagonist — fewer anti-androgenic / progestational side effects than spironolactone (no gynecomastia). Approved for HFrEF post-MI + resistant hypertension. Hyperkalemia risk; CYP3A4 substrate (avoid with strong inhibitors).

Half-Life & Elimination Curve (PO: 3h)

100%50%25%12.5%0%0h0×t½3h1×t½6h2×t½9h3×t½12h4×t½15h5×t½0×t½ (0h): 100% remaining (~0.586 mg/L)1×t½ (3h): 50% remaining (~0.293 mg/L)2×t½ (6h): 25% remaining (~0.147 mg/L)3×t½ (9h): 12.5% remaining (~73.3 µg/L)4×t½ (12h): 6.3% remaining (~36.6 µg/L)5×t½ (15h): 3.1% remaining (~18.3 µg/L)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
  • 0×t½0h100% (0.586 mg/L)
  • 1×t½3h50% (0.293 mg/L)
  • 2×t½6h25% (0.147 mg/L)
  • 3×t½9h12.5% (73.3 µg/L)
  • 4×t½12h6.3% (36.6 µg/L)
  • 5×t½15h3.1% (18.3 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.36h
Est. Peak (Cmax)0.586 mg/L
Clearance (CL)9.94 L/h
97% Washout (5×t½)15h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References